

Korean MDx Seegene's Allplex RV Master Assay approved in Australia

07 April 2022 | News

The test detects 21 targets for 19 respiratory viruses in a single tube, including COVID-19 and flu



Seegene Inc., South Korea's leading molecular diagnostics (MDx) company, has received approval from Australia's Therapeutic Goods Administration and achieved the European CE-IVD marking for its Allplex™ RV Master Assay which can distinguish 21 targets for 19 different respiratory viruses, including COVID-19, flu, and common colds.

Specifically, the assay can identify three genes of COVID-19, Flu A, Flu B, metapneumovirus, two types of respiratory syncytial virus, four types of parainfluenza virus, six types of adenovirus and three types of human rhinovirus. The syndromic test allows medical specialists to swiftly find out which viruses are making the patient sick with a single sample.

"Allplex™ RV Master Assay can detect respiratory viruses that can occur all year round to simplify the diagnostic of the 'new normal' respiratory virus composition," said Dr. Tove Havnhøj Frandsen of Sygehus Sønderjylland (Hospital of Southern Jutland)/RenTov Consult, who led Seegene's clinical test in Europe. "The assay is expected to be well-utilized as winter approaches in Australia and South America and as the world turns to live with COVID-19 endemically."